Inhibikase Therapeutics is a pharmaceutical company specializing in the development of therapies for Parkinson's Disease and gastrointestinal complications. They have two promising product candidates: IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, and IkT-001Pro, a preclinical anti-cancer agent prodrug. Inhibikase also conducts research programs for other neurological diseases and collaborates with several universities.